Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acurx PharmaceuticalsACXP +0.70%37 EV-to-EBIT is 0.58 as of Sep. 09, 2026. GuruFocus rates ACXP with a GF Score™ of 37/100. Among 365 Biotechnology companies, Acurx Pharmaceuticals ranks better than 84.11% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Acurx Pharmaceuticals's Enterprise Value for the quarter that ended in Jun. 2026 was $-3.99 Mil.
Acurx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acurx Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acurx Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acurx Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acurx Pharmaceuticals's EV-to-EBIT falls into.
Acurx Pharmaceuticals's current Enterprise Value is $-4.47 Mil.
Acurx Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.67 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acurx Pharmaceuticals (ACXP) has a EV-to-EBIT of 0.58 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acurx Pharmaceuticals and its competitors. According to the industry distribution chart, Acurx Pharmaceuticals ranks #58 out of 365 companies in the Biotechnology industry, placing it in the top 15.9%.
Is Acurx Pharmaceuticals' EV-to-EBIT too high?
Acurx Pharmaceuticals' current EV-to-EBIT is 0.58. The Biotechnology industry median EV-to-EBIT is 15.48. Acurx Pharmaceuticals' value of 0.58 is 96.3% below this industry median. Based on the distribution chart, Acurx Pharmaceuticals ranks #58 out of 365 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Acurx Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Acurx Pharmaceuticals' EV-to-EBIT compare to ENVB and HCWB?
According to the Biotechnology industry distribution chart, Acurx Pharmaceuticals ranks #58 out of 365 companies for EV-to-EBIT. This places Acurx Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.48. Acurx Pharmaceuticals' value of 0.58 is 96.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.48, based on 365 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Acurx Pharmaceuticals's current EV-to-EBIT of 0.58 is 96.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acurx Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acurx Pharmaceuticals's current EV-to-EBIT is 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acurx Pharmaceuticals stock overvalued right now?
Acurx Pharmaceuticals (ACXP) has a current EV-to-EBIT of 0.58. The current EV-to-EBIT is 0.58 and 96.3% below the Biotechnology industry median of 15.48. Acurx Pharmaceuticals' overall GF Score™ is 37/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Acurx Pharmaceuticals (ACXP), the current EV-to-EBIT is 0.58 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.
37GF Score
Get the complete analysis for ACXP
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACXP has been successfully added to your 
